Compile Data Set for Download or QSAR
Report error Found 62 Enz. Inhib. hit(s) with all data for entry = 1559
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330363(US9725434, 21 | 2-(3-Fluoro-2-{[(3R,6R)-6-methyl-1...)
Affinity DataIC50: 6nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330356(US9725434, 12 | (1S)-1-cyclopropyl- 1-(2-{[(3R,6R)...)
Affinity DataIC50: 13nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330354(US9725434, 9 | 2-(2-{[(3R,6R)-6-Methyl-1-{[2-(2H-1...)
Affinity DataIC50: 14nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330355(US9725434, 11 | (1R)-1-cyclopropyl- 1-(2-{[(3R,6R)...)
Affinity DataIC50: 14nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330378(US9725434, 36 | 2-(3-{[(3R,6R)-6-Methyl-1-{[2-(2H-...)
Affinity DataIC50: 18nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330368(US9725434, 27 | (1R)-6-{[(3R,6R)- 6-Methyl-1-{[2- ...)
Affinity DataIC50: 19nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330371(US9725434, 30 | (1S)-1-methyl-5-{[(3R,6R)-6-methyl...)
Affinity DataIC50: 20nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330346(US9725434, 4 | 2-(2-{[(3R,6R)-6-Methyl-1-{[2-(2H-1...)
Affinity DataIC50: 20nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330374(US9725434, 33 | 1-Methyl-6- {[(3R,6R)-6-methyl- 1-...)
Affinity DataIC50: 23nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330361(US9725434, 18 | 2-(3-{[(3R,6R)-6-Methyl-1-{[2-(2H-...)
Affinity DataIC50: 24nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330367(US9725434, 26 | (1S)-4- {[(3R,6R)-6- Methyl-1-{[2-...)
Affinity DataIC50: 25nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330351(US9725434, 6 | 2-(3-{[(3R,6R)-6-Methyl-1-{[2-(2H-1...)
Affinity DataIC50: 32nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330373(US9725434, 32 | (1S)-1-Methyl-4- {[(3R,6R)-6-methy...)
Affinity DataIC50: 34nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330357(US9725434, 15 | 1-Cyclopropyl-1-(3-{[(3R,6R)-6-met...)
Affinity DataIC50: 36nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330352(US9725434, 8 | 1-(2-{[(3R,6R)-6-methyl-1-{[2-(2H-1...)
Affinity DataIC50: 41nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330379(US9725434, 37 | 2-(3-{[(3R,6R)-6-Methyl-1-{[2-(2H-...)
Affinity DataIC50: 45nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330365(US9725434, 24 | 6-{[(3R,6R)-6- Methyl-1-{[2- (2H-1...)
Affinity DataIC50: 80nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330360(US9725434, 17 | 1-Cyclobutyl-1-(3-{[(3R,6R)-6-meth...)
Affinity DataIC50: 82nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330358(US9725434, 16 | 1-Cyclopentyl-1-(3-{[(3R,6R)-6-met...)
Affinity DataIC50: 86nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330347(US9725434, 5 | 1,1,1-Trifluoro-2-(3-{[(3R,6R)-6-me...)
Affinity DataIC50: 89nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330342(US9725434, 1 | 1-(3-{[(3R,6R)-6-Methyl-1-{[2-(2H-1...)
Affinity DataIC50: 98nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330376(US9725434, 34 | (1R)-1-Methyl-6- {[(3R,6R)-6- meth...)
Affinity DataIC50: 112nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330345(US9725434, 3 | 1-[3-({(3R,6R)-6-Methyl-1-[(2-pyrim...)
Affinity DataIC50: 119nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330370(US9725434, 29 | (1R)-1-Methyl-5-{[(3R,6R)-6-methyl...)
Affinity DataIC50: 123nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330377(US9725434, 35 | (1S)-1-Methyl-6- {[(3R,6R)-6- meth...)
Affinity DataIC50: 164nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330364(US9725434, 22 or 23 | 5-{[(3R,6R)-6-Methyl-1-{[2-(...)
Affinity DataIC50: 183nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330366(US9725434, 25 | (1R)-4- {[(3R,6R)-6- Methyl-1-{[2-...)
Affinity DataIC50: 238nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330356(US9725434, 12 | (1S)-1-cyclopropyl- 1-(2-{[(3R,6R)...)
Affinity DataIC50: 241nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330363(US9725434, 21 | 2-(3-Fluoro-2-{[(3R,6R)-6-methyl-1...)
Affinity DataIC50: 259nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330343(US9725434, 2 | 1-(3-{[(3R,6R)- 1-{[6-methoxy- 2-(2...)
Affinity DataIC50: 271nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330371(US9725434, 30 | (1S)-1-methyl-5-{[(3R,6R)-6-methyl...)
Affinity DataIC50: 289nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330355(US9725434, 11 | (1R)-1-cyclopropyl- 1-(2-{[(3R,6R)...)
Affinity DataIC50: 297nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330362(US9725434, 20 | 2-(4-Fluoro-3-{[(3R,6R)- 6-methyl-...)
Affinity DataIC50: 354nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330372(US9725434, 31 | (1R)-1-Methyl-4- {[(3R,6R)-6-methy...)
Affinity DataIC50: 390nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330369(US9725434, 28 | (1S)-6-{[(3R,6R)- 6-Methyl-1-{[2- ...)
Affinity DataIC50: 394nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330354(US9725434, 9 | 2-(2-{[(3R,6R)-6-Methyl-1-{[2-(2H-1...)
Affinity DataIC50: 436nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330373(US9725434, 32 | (1S)-1-Methyl-4- {[(3R,6R)-6-methy...)
Affinity DataIC50: 648nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330374(US9725434, 33 | 1-Methyl-6- {[(3R,6R)-6-methyl- 1-...)
Affinity DataIC50: 742nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330361(US9725434, 18 | 2-(3-{[(3R,6R)-6-Methyl-1-{[2-(2H-...)
Affinity DataIC50: 827nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330346(US9725434, 4 | 2-(2-{[(3R,6R)-6-Methyl-1-{[2-(2H-1...)
Affinity DataIC50: 996nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330376(US9725434, 34 | (1R)-1-Methyl-6- {[(3R,6R)-6- meth...)
Affinity DataIC50: 1.17E+3nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330368(US9725434, 27 | (1R)-6-{[(3R,6R)- 6-Methyl-1-{[2- ...)
Affinity DataIC50: 1.34E+3nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330352(US9725434, 8 | 1-(2-{[(3R,6R)-6-methyl-1-{[2-(2H-1...)
Affinity DataIC50: 1.52E+3nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330367(US9725434, 26 | (1S)-4- {[(3R,6R)-6- Methyl-1-{[2-...)
Affinity DataIC50: 1.53E+3nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330365(US9725434, 24 | 6-{[(3R,6R)-6- Methyl-1-{[2- (2H-1...)
Affinity DataIC50: 2.07E+3nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330357(US9725434, 15 | 1-Cyclopropyl-1-(3-{[(3R,6R)-6-met...)
Affinity DataIC50: 2.10E+3nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330377(US9725434, 35 | (1S)-1-Methyl-6- {[(3R,6R)-6- meth...)
Affinity DataIC50: 3.35E+3nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330358(US9725434, 16 | 1-Cyclopentyl-1-(3-{[(3R,6R)-6-met...)
Affinity DataIC50: 3.42E+3nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330345(US9725434, 3 | 1-[3-({(3R,6R)-6-Methyl-1-[(2-pyrim...)
Affinity DataIC50: 4.24E+3nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM330342(US9725434, 1 | 1-(3-{[(3R,6R)-6-Methyl-1-{[2-(2H-1...)
Affinity DataIC50: 4.51E+3nMAssay Description:The following table shows representative data for the compounds of the Examples as orexin receptor antagonists as determined by the FLIPR Ca2+ Flux A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent

Displayed 1 to 50 (of 62 total ) | Next | Last >>
Jump to: